Category: Workers Comp

599 posts found

WCRI Reports on the Impact of Marijuana Laws on Workers’ Comp Benefits

While recreational marijuana laws may be tied to increases in claim frequency, medical payments and prescriptions decreased, including those for opioids.

Legislation & Policy

State of the Nation with Sandy Shtab

Healthesystems VP of State & Industry Affairs comments on recent federal activity that creates potential impacts for workers’ comp.

Industry Trends

WCRI Publishes CompScope Benchmarks

A total of 14 reports capture workers’ comp data from 2018-2023 for 18 states, with information on medical payments and other metrics.

Healthe Developments

Diabetes Complicates Claims, Worker Recovery

Healthe’s VP of Clinical Services, Silvia Sacalis, BS, PharmD, shares her thoughts with Business Insurance in this recent article.

Clinical Insights

JAMA Finds High Prevalence of Depression and Anxiety in Chronic Pain Patients

A systematic review of 376 studies comprising almost 350,000 people with chronic pain saw 40% prevalence rates for depression and anxiety.

This Month's Must Read

Digital Therapeutics: The Promise of Better Health Outcomes for Injured Workers

What they are, the benefits, how they’re currently covered by insurers, and future outlooks.

Marijuana Developments

Massachusetts Considers Reimbursement, California Could Reject Medical Recommendation

A bill in Massachusetts could require insurers to pay for marijuana, while ACOEM recommends against marijuana for chronic pain guidelines.

Clinical Insights

WCRI Publishes Study on Degenerative and Comorbid Conditions

Approximately 38.8% of claims had one or more comorbidities, based on an analysis of 930,000 claims with at least 7 days lost time across 32 states.

Healthe Developments

Video Spotlight: How Obesity Can Complicate Workplace Injuries

Silvia Sacalis, VP of Clinical Services, chats with Business Insurance.

Healthe Developments

Visit Healthesystems at RISKWORLD 2025

Drop by Booth #824 for a copy of the 15th Anniversary edition of RxInformer magazine, and to learn how we’re transforming healthcare.

Medmonitor

FDA Declares Semaglutide Shortage Over

The GLP-1 receptor agonist has been considered in shortage since 2022, but the FDA confirmed with manufacturers that presented and projected demand can now be met.